High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study
Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, Jude EB
Nutrients · 112 citas
Cómo se estudió
- Diseño
- Estudio transversal (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute for Health and Care Research
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- National Institute for Health and Care Research (NIHR-INF-0556)
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2020-12-11 · Nutrients · vol. 12 · número 12 · pág. 3799
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 175 citas · más que el 100% de estudios similares · 20.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 23 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · Long-Term Effects of COVID-19
- Palabras clave
- Medicine, Cholecalciferol, Vitamin D and neurology, vitamin D deficiency, Internal medicine, Retrospective cohort study, Cohort study, Coronavirus disease 2019 (COVID-19), Cohort, Pediatrics, Disease, Infectious disease (medical specialty)
- MeSH
- humans, cholecalciferol, risk factors, cross-sectional studies, aged, aged, 80 and over, middle aged, female, male, united kingdom, covid-19, sars-cov-2, covid-19 drug treatment
7 autores
- Stephanie Fenxi Ling🇬🇧University of Manchester; Tameside and Glossop Integrated Care NHS Foundation Trust
- Eleanor Broad🇬🇧Tameside and Glossop Integrated Care NHS Foundation Trust
- Rebecca Murphy🇬🇧Tameside and Glossop Integrated Care NHS Foundation Trust
- Joseph M Pappachan🇬🇧Manchester Metropolitan University; Lancashire Teaching Hospitals NHS Foundation Trust; University of Manchester; Royal Preston Hospital
- Satveer Pardesi-Newton🇬🇧Leicester Royal Infirmary; University Hospitals of Leicester NHS Trust
- Marie‐France Kong🇬🇧Leicester General Hospital; University Hospitals of Leicester NHS Trust
- Edward Bernard Jude🇬🇧 · autor de correspondenciaManchester Metropolitan University; University of Manchester; Tameside and Glossop Integrated Care NHS Foundation Trust
Resumen
El texto original del estudio, en el idioma en que se publicó.
The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (ORadj 0.13, 95% CI 0.05-0.35, p adj 0.38, 95% CI 0.17-0.84, p = 0.018). In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. Further work with large population studies needs to be carried out to determine adequate serum 25(OH)D levels, as well as multi-dose clinical trials of cholecalciferol therapy to assess maximum efficacy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.